Ganga Pharmaceuticals (BOM:539680) EV-to-EBIT : 70.43 (As of May. 06, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Ganga Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ganga Pharmaceuticals's Enterprise Value is ₹130.79 Mil. Ganga Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.86 Mil. Therefore, Ganga Pharmaceuticals's EV-to-EBIT for today is 70.43.

The historical rank and industry rank for Ganga Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

BOM:539680' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.13 Med: 12.73 Max: 70.43
Current: 70.43

During the past 9 years, the highest EV-to-EBIT of Ganga Pharmaceuticals was 70.43. The lowest was 8.13. And the median was 12.73.

BOM:539680's EV-to-EBIT is ranked worse than
91.15% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.86 vs BOM:539680: 70.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ganga Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was ₹65.87 Mil. Ganga Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.86 Mil. Ganga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 2.82%.

Ganga Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Ganga Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ganga Pharmaceuticals EV-to-EBIT Chart

Ganga Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

8.13

9.14

21.98

26.03

31.08

Ganga Pharmaceuticals Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial													-	26.03	-	31.08	-

Competitive Comparison of Ganga Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ganga Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ganga Pharmaceuticals's EV-to-EBIT falls into.

Ganga Pharmaceuticals EV-to-EBIT Calculation

Ganga Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	130.793	/	1.857
	=	70.43

Ganga Pharmaceuticals's current Enterprise Value is ₹130.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ganga Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.86 Mil.

Ganga Pharmaceuticals (BOM:539680) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ganga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	1.857	/	65.873
	=	2.82 %

Ganga Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was ₹65.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ganga Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.86 Mil.

Ganga Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ganga Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ganga Pharmaceuticals (BOM:539680) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ganga Pharmaceuticals Ltd (BOM:539680) » Definitions » EV-to-EBIT

Traded in Other Exchanges

N/A

Address

Dhanvantri Marg, Gangatat, Gopcharpada, Near Digi 1 Electronic Showroom, Virar (East), Palghar, MH, IND, 401305

Website

https://www.ayurvedganga.com

Ganga Pharmaceuticals Ltd is an India based producer of Bulk ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.

Ganga Pharmaceuticals (BOM:539680) Headlines

No Headlines